Overview

Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

Status:
Completed

Trial end date:
2020-03-02

Target enrollment:

Participant gender:

Summary

This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia (LID)

Phase:

Phase 2

Details

Lead Sponsor:

Prexton Therapeutics

Treatments:

Levodopa